By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GENFIT Corp. 

245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405


SEARCH JOBS
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001


Key Statistics


Email: Karen.Miller@Genfit.com
Ownership: Public

Web Site: GENFIT
Employees: 125 (Scientists: 100)
Symbol: ALGFT
 









Company News
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/27/2015 7:05:21 AM
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015 12:07:14 PM
GENFIT Corp. (ALGFT): Minutes Of The Combined General Shareholders' Meeting Of February 24, 2015 2/24/2015 11:16:09 AM
GENFIT Corp. (ALGFT) Announces Its Turnover And Cash Situation As Of December 31, 2014 2/20/2015 11:03:33 AM
GENFIT Corp. (ALGFT) Announces Its Financial Calendar For 2015 1/27/2015 12:13:50 PM
GENFIT Corp. (ALGFT) To Hold A Combined General Sharehoders’ Meeting On February 24, 2015 1/19/2015 11:44:20 AM
GENFIT Corp. (ALGFT): A Clinical Study Demonstrates The Safety Of Gft505 On Cardiac Activity 1/6/2015 9:05:34 AM
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014 9:35:14 AM
GENFIT Corp. (ALGFT) Wins The Enternext Prize For The Most Successful Financial Operation Of The Year 12/3/2014 1:10:58 PM
GENFIT Corp. (ALGFT) To The Distinguished 'Investor Awards 2014' And Organized By Boursorama Morningstar 12/1/2014 2:21:16 PM
1234567
//-->